Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

BeiGene

Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (.

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Molecular Partners AG

Molecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be.

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Basel, April 27, 2022 — Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 expression. Novartis intends to submit these data to regulatory authorities, and will collaborate with BeiGene to present them at an upcoming medical meeting.

Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study

Growing quarterly numbers but below market expectations. Withdrawal from Russia manageable.

Novartis: Comment On Q1 Results

Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth

Novartis AG (NYSE:NVS ) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Simon Baker - Redburn Matthew Weston - Credit Suisse Wimal Kapadia - Bernstein Andrew Baum - Citi Richard Vosser - JPMorgan Emmanuel Papadakis - Deutsche Bank Emily Field - Barclays Tim Anderson - Wolfe Research Peter Welford - Jefferies Keyur Parekh - Goldman Sachs Florent Cespedes - Societe Generale Sarita Kapila - Morgan Stanley Steve Scala - Cowen Laura Sutcliffe - UBS Seamus Fernandez - Guggenheim Securities Kerry Holford - Berenberg Naresh Chouhan - Intron Health Richard Parkes - BNP Paribas Graham Parry - Bank of America Matthew Weston - Credit Suisse Andrew Baum - Citi Steve Scala - Cowen Operator Good morning and good afternoon. And welcome to the Novartis Q1 2022 Results Release Conference Call and Live Webcast.

Novartis AG (NVS) CEO Vasant Narasimhan on Q1 2022 Results - Earnings Call Transcript

Sales of the company's heart failure treatment Entresto rise 39% in the first quarter.

Novartis Earnings Get a Boost From Sales of Its Key Drugs

Sales of heart failure treatment Entresto rise 39% in the first quarter.

Novartis Earnings Get Boost From Sales of Key Drugs

Novartis on Tuesday posted rising earnings and sales for the first quarter of the year as its key drugs drove the business and generics division Sandoz continued to normalize after Covid-19 headwinds.

Novartis posts higher net profit of $2.22 billion on sales of $12.53 billion

Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.

Novartis earnings edge higher on Cosentyx, Entresto

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Snowflake

Novartis recently joined Snowflake's newly-launched Healthcare Data Cloud, which aims to create an integrated and cross-cloud data platform.

Novartis and Snowflake: Driving healthcare data innovation

The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.

Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug

Big pharma company Novartis pays big dividends -- but there are other reasons for investors to buy its stock.

Here's 1 High-Yield Dividend Stock to Consider Buying

Basel, April 22, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization of Tabrecta® (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer

BioMarin Pharmaceutical

CRISPR Therapeutics

Intercept Pharma

Ionis Pharma

Mirati Therapeutics

Sarepta Therapeutics

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.

7 Potential Biotech Stocks Buyout Targets in 2022

Allianz SE

Colgate-Palmolive

Carlisle Companies

Enbridge

Alphabet

Lowe's

Mastercard

Realty Income Corp

PPG Industries

Recession fears are rising thanks to the 8.5% consumer inflation and 11.2% wholesale inflation. Never in history has US inflation gone above 5% without a recession following within a few years. Fortunately, the economic data indicates the US economy is strong, and any potential recession is coming in late 2023 or possibly in 2024 or even 2025.

11 Incredible Blue-Chip Bargains For The Ultimate Sleep Well At Night Retirement Portfolio

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

These stocks are bright spots in an overall dismal market for biotech stocks.

3 Fantastic Biotech Stocks to Buy in April

Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss newspaper Tages-Anzeiger reported on Tuesday, citing unnamed company sources.

Novartis to cut thousands of jobs in global revamp - paper

Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.

Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer

The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.

Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder

Basel, April 6 , 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.1 Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.2,3 In accordance with the Accelerated Approval Program, continued approval may be contingent upon verification and description of clinical benefit from confirmatory evidence.

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Altria

The bond market is starting to signal that a recession and bear market could be coming in 2023 or 2024.

5% Yielding Dividend Aristocrats You'll Want To Own In The Coming Bear Market

Novartis ( NVS , Financial) investors hope the organizational changes the company is making can shake loose some shareholder value. Since February 2020, Novartis stock has dropped nearly 12% while the Invesco Dynamic Pharmaceuticals ETF ( PJP , Financial) has climbed more than 25%.

Changes at Novartis Aimed at Boosting Shareholder Value

News for Novartis Stock (NVS)